{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"14.7","value":"6.5"},{"comment":"PFS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"1.7","upperLimit":"NA","value":"NA"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"1.8","upperLimit":"NA","value":"6.4"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"8.7","value":"5.3"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"6.4","value":"3.7"},{"comment":"PFS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG005","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"7.2","upperLimit":"17.3","value":"9.1"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"3.6","upperLimit":"NA","value":"7.7"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG008","lowerLimit":"1.8","upperLimit":"NA","value":"6.2"},{"groupId":"OG009","lowerLimit":"5.5","upperLimit":"12.0","value":"9.4"},{"groupId":"OG010","lowerLimit":"1.8","upperLimit":"3.8","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"14"},{"groupId":"OG010","value":"19"}],"units":"Participants"}],"description":"Time from first dose of study drug to the earliest documented evidence of PD or death due to any cause. Participants who undergo surgical resection of target or non-target lesions, who have received other anticancer treatments, including surgical resection or radiation (other than palliative radiation to pre-existing bone metastases'), or who do not have a documented date of progression or death due to any cause will be censored at the date of the last assessment. PD per RECIST v1.1 is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions. mRECIST used for pleural mesothelioma defines PD as an increase of at least 20% in the sum of the diameters of viable target lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG000","title":"Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG001","title":"Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in triple-negative breast cancer (TNBC). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG002","title":"Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in triple-negative breast cancer (TNBC). Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG003","title":"Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG004","title":"Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG005","title":"Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG006","title":"Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG007","title":"Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG008","title":"Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG009","title":"Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG010","title":"Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First Dose of Study Drug to PD or Death due to Any Cause (Up to 2.61 years)","title":"Progression-free-survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}